Search Results 441-450 of 16632 for alopecia

1. KTX-100 MMSET Catalytic Inhibitor that Suppresses H3K36me2 in Patients with Relapsed and Refractory Multiple Myeloma - Mayo Clinic

   Recovery to Grade ≤ 1 for any nonhematologic toxicities due to prior therapy, excluding alopecia or Grade 2 neuropathy. Ability and willingness to adhere ...

2. A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma - Mayo Clinic

   Recovery from non-hematologic toxic effects of prior therapy to grade ≤ 1 (except alopecia) by NCI CTCAE Version 4.03. Adequate bone marrow (BM), renal ...

3. Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer

   Resolution of all acute toxic effects of prior induction anti-HER2-based chemotherapy regimen to NCI CTCAE version 4.0 Grade ≤1 (except alopecia or other ...

4. Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic - Mayo Clinic

   with ongoing alopecia of any grade will be eligible; Patient must have a life expectancy of >= 3 months, as estimated by the treating oncologist; Patient must ...

5. MEDI5395 Advanced Solid Tumors - Mayo Clinic

   Participation eligibility · Vitiligo or alopecia; · Hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement; · Any chronic skin condition ...

6. A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers - Mayo Clinic

   (Exceptions include stable toxicities as a result of previous therapy such as alopecia, well controlled electrolyte or endocrine abnormalities, peripheral ...

7. University of California Minority Patient-Derived Xenograft (PDX) Development and Trial Center (UCaMP) to Reduce Cancer Health Disparities - Mayo Clinic

   About this study. The purpose of this study is to establish at least 200 patient-derived cancer xenografts (PDXs), and to utilize these PDXs in preclinical ...

8. A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU) - Mayo Clinic

   Recovery to ≤ Grade 1 of any clinically significant toxicity (excluding alopecia) rior to randomization. Subject must have adequate bone marrow, renal and ...

9. A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients With AML - Mayo Clinic

   0) from all nonhematological toxicities except for alopecia; Known clinically active human immunodeficiency virus, active hepatitis B or active hepatitis C ...

10. A Study of Subcutaneous Nivolumab + Relatlimab FDC in Previously Untreated Metastatic or Unresectable Melanoma - Mayo Clinic

    Skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment;; Conditions not expected to recur in the absence of an external ...